Clinical Spotlight Series: Hypertriglyceridemia & CV Health-3. Multifactorial sHTG and FCS: What You Need to Know

Video Transcription

Video Summary

The speaker discloses prior research and advisory roles with Ionis and Arrowhead, then reviews severe hypertriglyceridemia (TG >500, especially >1,000) where preventing pancreatitis becomes the priority. Patients with very high TG are grouped into: (1) genetically confirmed familial chylomicronemia syndrome (FCS), (2) “clinical/functional” chylomicronemia with negative genetic testing but persistent, refractory TG elevations, and (3) episodic cases driven by secondary factors (e.g., uncontrolled diabetes, alcohol) on top of milder genetic risk.<br /><br />They explain normal triglyceride clearance via lipoprotein lipase (LPL) and the five key proteins/genes involved (LPL, LMF1, GPIHBP1, APOC2, APOA5). FCS (autosomal recessive defects in these pathways) causes persistent chylomicronemia, very high TG with relatively low ApoB/LDL, poor response to fibrates and omega-3s, and early, recurrent pancreatitis plus signs like eruptive xanthomas and lipemia retinalis.<br /><br />Management centers on an extremely low-fat diet and emerging ApoC3-lowering therapies (ASO/siRNA) that improve remnant clearance. Multifactorial/secondary cases often improve when triggers are treated and may respond to standard therapies.

Keywords

severe hypertriglyceridemia

familial chylomicronemia syndrome

lipoprotein lipase

ApoC3-lowering therapies

pancreatitis prevention